Moderna and Merck Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

By Adam Feuerstein and Andrew Joseph · STAT News · 2026-10-22

Moderna and Merck Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

According to reporting from STAT News, a Phase 2 study of an individualized mRNA therapy significantly improved outcomes for melanoma patients. The trial conducted by Merck and Moderna demonstrated that combining their personalized vaccine with standard care helped participants l

According to reporting from STAT News, a Phase 2 study of an individualized mRNA therapy significantly improved outcomes for melanoma patients. The trial conducted by Merck and Moderna demonstrated that combining their personalized vaccine with standard care helped participants l